18.80USD-2.79%Mkt Cap: —P/E: —1d ago
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for …
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap—
Enterprise Value2.16B $
Revenue (TTM)1.97B $
Gross Profit-341.55M $
Net Income (TTM)-136.72M $
Revenue/Share19.00 USD
Last Price18.80 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees835
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS8036071004
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-123.40
EV/Revenue1.10
P/S—
P/B1.24
EPS (TTM)-4.29
EPS (Forward)—
52W Range
17.8941% of range20.10
52W High20.10 USD
52W Low17.89 USD
Profitability
Gross Margin-17.30%
Oper. Margin13.03%
EBITDA Margin-0.89%
Profit Margin-6.93%
ROE-9.48%
ROA-1.13%
Growth
Revenue Growth-34.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF111.01M $
CapEx (TTM)—
FCF Margin1.12%
FCF Yield—
Net Debt273.92M $
Net Debt/EBITDA-15.62
Balance Sheet
Debt/Equity69.54
Current Ratio4.42
Quick Ratio2.44
Book Value/Sh14.46 USD
Cash/Share7.465 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.66.82M
Float101.04M
Insiders4.93%
Institutions103.59%
Technical
SMA 50121.03 (-84.5%)
SMA 200112.45 (-83.3%)
Beta0.20
S&P 52W Chg20.80%
Avg Vol (30d)16.73K
Avg Vol (10d)365
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—